Time Restricted Feeding on Nonalcoholic Fatty Liver Disease ( TREATY-FLD ):a 12-month Follow-up Study
TREATY-FLD
Effects of Time-Restricted Feeding on Nonalcoholic Fatty Liver Disease in Obese Adults: a 12-month Randomized Clinical Trial
1 other identifier
interventional
88
1 country
1
Brief Summary
Time restricted feeding (TRF) is a novel type of intermittent calorie restriction diet that involves eating a daily period of 8 hours or less. This is a 6-month follow-up study of TREATY-FLD trial to evaluate the effect of time restricted feeding (TRF) on hepatic fat contents and cardiometabolic risk factors in obese adults over 6 months compared to continuous energy restriction (CER).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jul 2021
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 30, 2021
CompletedFirst Submitted
Initial submission to the registry
July 31, 2021
CompletedFirst Posted
Study publicly available on registry
August 3, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 30, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
December 30, 2021
CompletedApril 6, 2022
April 1, 2022
5 months
July 31, 2021
April 5, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in intrahepatic fat content
Intrahepatic fat content will be assessed by MR mDixon-Quant
Baseline,month 6, month 12.
Secondary Outcomes (10)
Change in liver fiber
Baseline,month 6, month 12.
Change in visceral fat
Baseline,month 6, month 12.
Change in body fat
Baseline,month 6, month 12.
Change in waist circumference
Baseline,month 6, month 12.
Change in body weight
Baseline,month 6, month 12.
- +5 more secondary outcomes
Study Arms (2)
Time Restricted Feeding
EXPERIMENTALParticipants will receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women during a window of 8 h/d (8 am to 4 pm).
Continuous Energy Restriction
ACTIVE COMPARATORParticipants will follow receive a diet of 1500-1800kcal/ d for men and 1200-1500kcal/d for women, without restriction on feeding time.
Interventions
Participants will receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women during a window of 8 h/d (8 am to 4 pm).
Participants will follow receive a diet of 1500-1800kcal/ d for men and 1200-1500kcal/d for women, without restriction on feeding time.
Eligibility Criteria
You may qualify if:
- Man or women aged≥18 years;
- Subjects with NAFLD determined by MRI (intrahepatic triglyceride content ≥5%);
- Body mass index (BMI)of 28.0 to 45.0 kg/m2;
You may not qualify if:
- History of alcoholic liver disease, chronic viral hepatitis, drug-induced hepatitis, autoimmune hepatitis, cirrhosis, and liver cancer;
- History of HIV, or active pulmonary tuberculosis;
- Diagnosis of type 1 and type 2 diabetes;
- History of malignant tumors;
- Serious liver dysfunction or chronic kidney disease (AST or ALT \> 3 times the upper limit of normal, or eGFR\<30 ml/min/1.73 m2);
- Significant alcohol consumption in the past six months (Consumed more than 20 g/day for women or 30 g/day for men);
- History of serious cardiovascular or cerebrovascular disease (angina, myocardial infarction or stroke) in the past 6 months;
- History of severe gastrointestinal diseases or gastrointestinal surgery in the past 12 months;
- History of Cushing's syndrome, hypothyroidism, acromegaly, hypothalamic obesity;
- Being a smoker or having been a smoker in the 3 months prior to their screening visit;
- Taking medications affecting weight or energy intake/energy expenditure in the last 6 months, including weight loss medications, antipsychotic drugs or other medications as determined by the study physician;
- Currently participating in weight loss programs or weight change in the past 3 months (\> 5% current body weight) ;
- Women who are pregnant or plan to become pregnant;
- Patients who cannot be followed for 24 months (due to a health situation or migration);
- Patients who are unwilling or unable to give informed consent.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, 510515, China
Related Publications (1)
Wei X, Lin B, Huang Y, Yang S, Huang C, Shi L, Liu D, Zhang P, Lin J, Xu B, Guo D, Li C, He H, Liu S, Xue Y, Xu Y, Zhang H. Effects of Time-Restricted Eating on Nonalcoholic Fatty Liver Disease: The TREATY-FLD Randomized Clinical Trial. JAMA Netw Open. 2023 Mar 1;6(3):e233513. doi: 10.1001/jamanetworkopen.2023.3513.
PMID: 36930148DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Huijie Zhang, MD,PhD
Department of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Deputy director of Department of Endocrinology and Metabolism
Study Record Dates
First Submitted
July 31, 2021
First Posted
August 3, 2021
Study Start
July 30, 2021
Primary Completion
December 30, 2021
Study Completion
December 30, 2021
Last Updated
April 6, 2022
Record last verified: 2022-04